A synthetic six-amino-acid peptide that stimulates growth hormone release through the ghrelin receptor. It was developed after GHRP-6 as a more potent compound with a weaker appetite effect.

How is GHRP-2 different from GHRP-6?

It is described in published work as more potent at releasing growth hormone, with less appetite stimulation and less cortisol and prolactin spillover. Both act on the same ghrelin receptor.

How is GHRP-2 different from Ipamorelin?

Ipamorelin is more selective. It was characterised as releasing growth hormone without meaningfully raising cortisol or prolactin even at very high doses, whereas GHRP-2 retains some of that spillover. GHRP-2 is generally described as the more potent of the two at raising growth hormone.

Why are older GHRPs still studied if newer ones are more selective?

Because selectivity and potency are a trade-off rather than a straight ranking. The three compounds sit at different points on that trade-off, and different research questions call for different points.

Research Library›Growth Hormone & Endocrine›GHRP-2

Second-Generation GHRP

GHRP-2: The Middle Step Between Discovery and Precision

More potent than the compound that came before it, less selective than the one that came after. GHRP-2 is the second draft of the growth hormone secretagogue idea, and it shows exactly what the field was trying to solve.

6 min read·4 studies cited·Updated July 2026

Evidence level

Human trial evidence exists — no regulatory approval

What this level means

Quick Reference

Class	GHRP — ghrelin receptor agonist
Generation	Second (after GHRP-6)
Receptor	GHS-R1a (ghrelin receptor)
Relative to GHRP-6	More potent, less appetite effect
Relative to Ipamorelin	Less selective

What Is GHRP-2?

GHRP-2 is a synthetic hexapeptide that triggers growth hormone release through the ghrelin receptor — the same pathway as GHRP-6, but developed afterwards with a specific problem in mind.

GHRP-6 had proved the pathway existed and could be triggered. Its drawback was that it triggered a good deal besides: pronounced appetite stimulation, and increases in cortisol and prolactin alongside the growth hormone. GHRP-2 was an attempt to keep the useful part and reduce the rest.

The family progression, in plain language: think of tuning a radio. GHRP-6 found the station but brought a lot of static with it — you could hear the music, along with everything either side of it. GHRP-2 narrowed the tuning: stronger signal, less noise, though some bleed-through remained. Ipamorelin, arriving later, is the sharply tuned receiver that picks up the one station cleanly. Each step is the same broadcast, received with progressively less interference.

What Actually Changed

Compared with GHRP-6, published work describes GHRP-2 as more potent at prompting growth hormone release, with a weaker appetite effect. It remains a ghrelin receptor agonist, so appetite stimulation is not eliminated — it is reduced.

The cortisol and prolactin question is where the family’s later development focused. GHRP-2 produces less of this spillover than GHRP-6, but measurably more than Ipamorelin, which was characterised specifically for releasing growth hormone without meaningful effect on those hormones even at very high doses.

This is why all three still appear in the research literature. They are not simply better and worse versions of one another — they are three points on a potency-versus-selectivity trade-off, and different research questions call for different points on it.

Where the Evidence Stands

GHRP-2 has been studied more extensively in humans than most compounds in this family, appearing in work on growth hormone deficiency diagnosis and in studies of GH release profiles. It has been examined as a diagnostic tool — provoking a measurable growth hormone response to assess pituitary function.

It holds no regulatory approval for therapeutic use. As with the rest of the GHRP family, most published work is either preclinical or short-duration clinical characterisation rather than long-term outcome data.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cellular and molecular life sciences : CMLS, 1998. PubMed
Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European journal of endocrinology, 1998. PubMed
Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, et al. “Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.” Clinical Medicine Insights. Cardiology, 2017. PubMed
Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews, 2018. PubMed